Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,210.10",
    "chg": -1.9,
    "chgp": "-0.16%",
    "dir": -1,
    "prev_price": "1,212.00",
    "mcapval": "101,230.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Sep 23, 03:30 PM",
    "curr_time": "05:57 AM",
    "last_traded_at": "Sep 23, 03:30 PM IST",
    "bse_nse_vol": "10.31 lacs",
    "exc_status": "Active",
    "traded_date": "Sep 23, 2026",
    "traded_date_str": "2026 09 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 31.4 vs Industry's 37.44: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-4201946",
        "imagepath": "",
        "date": "2026-09-23 09:21:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 31.4, which is approximately 16% below the Pharmaceuticals & Biotechnology industry average of 37.44. This discount suggests the market is pricing in either a relative undervaluation or concerns about near-term earnings growth compared to peers. The sector’s elevated P/E reflects investor willingness to pay a premium for growth and innovation, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> remains comparatively conservative in valuation terms. <a href=\"https://www.market..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-amid-mixed-market-signals-4200357",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/DrReddysLaborat_technicaldot_4200357.png",
        "date": "2026-09-22 08:05:24",
        "description": "Dr Reddys Laboratories Ltd has experienced a subtle but notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a 2.64% gain on 22 Sep 2026, the pharmaceutical mid-cap’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and volume-based metrics. This analysis delves into the recent technical parameter changes, contextualising them within the broader market and sector performance."
      },
      {
        "title": "P/E at 30.34 vs Industry's 37.18: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-4199298",
        "imagepath": "",
        "date": "2026-09-21 09:20:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index confers Dr Reddys Laboratories Ltd a strategic advantage in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange, serves as a barometer for the Indian equity market. Inclusion in this elite group ensures that the stock attracts considerable institutional interest, including from mutual funds, pension funds, and exchange-traded funds (ETFs) that track the benchmark.</p>\n                <p>Dr Reddys’ market capitalisation currently stands at ₹99,994.70 crores, categorising it as a mid-cap stock within the pharmaceutical sector. This sizeable valuation supports its continued presence in t..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-sell-4198010",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/DrReddysLaborat_mojoScore_4198010.png",
        "date": "2026-09-19 10:10:04",
        "description": "Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 13 July 2026, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 19 September 2026, providing investors with the latest insights into its performance and prospects."
      },
      {
        "title": "P/E at 30.36 vs Industry's 36.93: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-4196913",
        "imagepath": "",
        "date": "2026-09-18 09:20:45",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands at 30.36, which is approximately 17.8% below the Pharmaceuticals & Biotechnology industry average of 36.93. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or perceives higher risks relative to its peers. The sector’s elevated P/E reflects optimism about growth prospects, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades with a valuation that may indicate a more conservative stance. Investors might wo..."
      },
      {
        "title": "P/E at 29.67 vs Industry's 36.44: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-challenges-amid-nifty-50-membership-4195878",
        "imagepath": "",
        "date": "2026-09-17 09:20:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry Average</strong></p>\n                <p>The current P/E ratio of 29.67 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> represents a discount of approximately 18.5% relative to the sector’s average of 36.44. This valuation gap suggests that the market is pricing in either a subdued growth outlook or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations driven by innovation and patent portfolios, this discount is analytically significant. It raises the question of whether the stock’s lower valuation is justified by fundamentals or if it presents a valuation anomaly — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-..."
      },
      {
        "title": "P/E at 29.78 vs Industry's 36.52: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-nifty-50-membership-significance-4194618",
        "imagepath": "",
        "date": "2026-09-16 09:20:48",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discounted P/E Amid Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> currently trades at a P/E of 29.78, which is approximately 18.5% below the Pharmaceuticals & Biotechnology industry average of 36.52. This discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Given the sector’s generally elevated valuations, the stock’s lower P/E could reflect concerns about recent earnings momentum or broader sector headwinds. The valuation gap invites the question <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"ctx\">previously rated Hold, what is Dr Reddy..."
      },
      {
        "title": "P/E at 30.07 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-sell-grade-amid-mixed-performance-and-institutional-shifts-4192877",
        "imagepath": "",
        "date": "2026-09-15 09:20:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands at 30.07, which is approximately 18.8% lower than the Pharmaceuticals & Biotechnology industry average of 37.05. This discount suggests that the market is pricing in either a relative undervaluation or concerns about the company’s near-term earnings growth compared to its peers. Given the sector’s elevated valuation, this gap is significant and invites scrutiny of the underlying fundamentals and market sentiment. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a>’s mid-cap status ..."
      },
      {
        "title": "P/E at 29.55 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-nifty-50-membership-significance-4189983",
        "imagepath": "",
        "date": "2026-09-11 09:20:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry Average</strong></p>\n                <p>The current P/E ratio of 29.55 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> represents a discount of approximately 20.3% relative to the sector’s average of 37.05. This valuation gap suggests the market is pricing in either subdued growth prospects or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations due to steady earnings and innovation potential, this discount merits closer scrutiny. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a>’s mid-cap status with a market capitalisation of ₹95,099.26 crores pla..."
      }
    ],
    "total": 677,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending September 30 2026.",
      "datetime": "22-Sep-2026",
      "details": "Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 inter alia to consider and approve Unaudited Standalone and Consolidated Financial results of the Company for the quarter ending September 30 2026.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "22-Sep-2026",
      "details": "Closure of Trading window",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "21-Sep-2026",
      "details": "Intimation of analyst meet",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "23 Oct 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 26",
          "dt": "2026-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 31.4 vs Industry's 37.44: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-23 09:21:11

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 31.4, which is approximately 16% below the Pharmaceuticals & Biotechnology industry average of 37.44. This discount suggests the market is pricing in either a relative undervaluation or concerns about near-term earnings growth compared to peers. The sector’s elevated P/E reflects investor willingness to pay a premium for growth and innovation, yet Dr Reddys Laboratories Ltd remains comparatively conservative in valuation terms. Read full news article

Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-09-22 08:05:24

Dr Reddys Laboratories Ltd has experienced a subtle but notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a 2.64% gain on 22 Sep 2026, the pharmaceutical mid-cap’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and volume-based metrics. This analysis delves into the recent technical parameter changes, contextualising them within the broader market and sector performance.

Read full news article

P/E at 30.34 vs Industry's 37.18: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-21 09:20:51

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers Dr Reddys Laboratories Ltd a strategic advantage in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange, serves as a barometer for the Indian equity market. Inclusion in this elite group ensures that the stock attracts considerable institutional interest, including from mutual funds, pension funds, and exchange-traded funds (ETFs) that track the benchmark.

Dr Reddys’ market capitalisation currently stands at ₹99,994.70 crores, categorising it as a mid-cap stock within the pharmaceutical sector. This sizeable valuation supports its continued presence in t...

Read full news article

Dr Reddys Laboratories Ltd is Rated Sell

2026-09-19 10:10:04

Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 13 July 2026, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 19 September 2026, providing investors with the latest insights into its performance and prospects.

Read full news article

P/E at 30.36 vs Industry's 36.93: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-18 09:20:45

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 30.36, which is approximately 17.8% below the Pharmaceuticals & Biotechnology industry average of 36.93. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or perceives higher risks relative to its peers. The sector’s elevated P/E reflects optimism about growth prospects, yet Dr Reddys Laboratories Ltd trades with a valuation that may indicate a more conservative stance. Investors might wo...

Read full news article

P/E at 29.67 vs Industry's 36.44: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-17 09:20:59

Valuation Picture: Discount to Industry Average

The current P/E ratio of 29.67 for Dr Reddys Laboratories Ltd represents a discount of approximately 18.5% relative to the sector’s average of 36.44. This valuation gap suggests that the market is pricing in either a subdued growth outlook or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations driven by innovation and patent portfolios, this discount is analytically significant. It raises the question of whether the stock’s lower valuation is justified by fundamentals or if it presents a valuation anomaly — Read full news article

P/E at 29.78 vs Industry's 36.52: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-16 09:20:48

Valuation Picture: Discounted P/E Amid Sector Premiums

Dr Reddys Laboratories Ltd currently trades at a P/E of 29.78, which is approximately 18.5% below the Pharmaceuticals & Biotechnology industry average of 36.52. This discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Given the sector’s generally elevated valuations, the stock’s lower P/E could reflect concerns about recent earnings momentum or broader sector headwinds. The valuation gap invites the question previously rated Hold, what is Dr Reddy...

Read full news article

P/E at 30.07 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-15 09:20:51

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 30.07, which is approximately 18.8% lower than the Pharmaceuticals & Biotechnology industry average of 37.05. This discount suggests that the market is pricing in either a relative undervaluation or concerns about the company’s near-term earnings growth compared to its peers. Given the sector’s elevated valuation, this gap is significant and invites scrutiny of the underlying fundamentals and market sentiment. Dr Reddys Laboratories Ltd’s mid-cap status ...

Read full news article

P/E at 29.55 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-11 09:20:55

Valuation Picture: Discount to Industry Average

The current P/E ratio of 29.55 for Dr Reddys Laboratories Ltd represents a discount of approximately 20.3% relative to the sector’s average of 37.05. This valuation gap suggests the market is pricing in either subdued growth prospects or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations due to steady earnings and innovation potential, this discount merits closer scrutiny. Dr Reddys Laboratories Ltd’s mid-cap status with a market capitalisation of ₹95,099.26 crores pla...

Read full news article

View All News